Rigel Pharmaceuticals. has been granted a patent for kinase inhibitory compounds, specifically targeting receptor-interacting protein-1 (RIP1) kinase. These compounds may be used in pharmaceutical compositions to treat or prevent various diseases associated with RIP1, including amyotrophic lateral sclerosis, type I diabetes, and rheumatoid arthritis. GlobalData’s report on Rigel Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Rigel Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Rigel Pharmaceuticals's grant share as of June 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12043629B2 outlines methods for treating various diseases associated with receptor-interacting protein-1 (RIP1) kinase. The claims specify that a therapeutically effective amount of a compound, referred to as Formula I, can be administered to subjects diagnosed with or suspected of having diseases such as amyotrophic lateral sclerosis (ALS), type I diabetes, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, asthma, or leukemia. The patent also encompasses pharmaceutical compositions that include Formula I along with one or more pharmaceutically acceptable excipients, emphasizing the versatility of the treatment approach across multiple conditions linked to RIP1 kinase.
Additionally, the patent includes claims focused on the inhibition of RIP1 kinase in subjects, reiterating the therapeutic potential of the compounds described. The methods outlined in the claims are designed to provide effective treatment options for patients suffering from the specified diseases, highlighting the importance of targeting RIP1 kinase as a therapeutic strategy. The claims further categorize the diseases into specific groups, allowing for targeted treatment protocols based on the condition being addressed. Overall, the patent presents a comprehensive framework for utilizing compounds of Formula I in the management of diseases associated with RIP1 kinase activity.
To know more about GlobalData’s detailed insights on Rigel Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
